Phase 2 N=100 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
Hepatocellular Carcinoma · Metastasis · Invasion
Primary: Overall Survival — 333; 290 days — p=0.4593
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=474 The Use of Public Messaging for the Promotion of Firearm Safety to Veterans
Injuries
Primary: Number of Participants With Self-reported Injury Prevention Belief — 66; 73; 57; 49 Participants
N/A N=63 Nutritional Therapy Interventions in Heart Failure
Heart Failure NYHA Class II
Primary: Functional Test — 115.91; 57.25 feet
Phase 3 N=784 Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment — -17.09; -18.94; -21.95; -18.22 units on a scale — p=0.4702
Phase 4 N=251 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Epilepsy, Partial
Primary: Number of Patients With Adverse Events (AEs) — 184 Participants
Phase 3 N=193 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
Hematologic Diseases · Anemia, Sickle Cell
Primary: Treatment Differences of the Change in Qualitative Splenic Function From Baseline — 19; 28; 51; 46 Participants — p=0.21
Phase 2 N=7 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
CIDP · Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Muscle Strength
N/A N=1,536 Shared Health Appointments and Reciprocal Enhanced Support
Diabetes Insipidus
Primary: Change in Glycemic Control — 8.92; 9.12; 8.26; 8.16 % glycolated hemoglobin
N/A N=30 Effectiveness of CES on Emotional and Cellular Wellbeing
Anxiety · Depression
Primary: HADS Questionnaire Combined Score — 20.3077; 19.909; 11.1538; 15.4545 score on a scale — p=.013
N/A N=31 Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation
Respiratory Distress Syndrome in Premature Infants · Very Low Birth Weight Baby
Primary: Maximum Factional Inspired Oxygen Percent (FiO2) — 48; 39 percentage of Inspired Oxygen — p=0.0012
N/A N=206 A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence
Fecal Incontinence
Primary: Percentage of Participants Who Are Responder50. — 71; 21 Participants
Phase 3 N=2,272 Long Term Safety Study of Plecanatide
Irritable Bowel Syndrome
Primary: Number of Participants With Treatment Related Adverse Events. — 205 Participants
Phase 3 N=61 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
Parkinson's Disease (PD)
Primary: Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score — -2.33; -17.37 units on a scale — p=<0.0001
N/A N=16 Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge
Celiac Disease
Primary: Change From Baseline in Small Intestine Histology Based on Villous Height to Crypt Depth (Vh:Cd) Ratio — 2.10; 2.30; -0.06; -1.53 ratio — p=0.385
N/A N=33 Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study
Oropharyngeal Cancer
Primary: Performance — 0 Participants